Global Canine Cancer Screening Services Market Strategic Research Report

Scope of the Report

The global Canine Cancer Screening Services market size is predicted to grow from US$ 208 million in 2025 to US$ 335 million in 2032; it is expected to grow at a CAGR of 7.1% from 2026 to 2032.

Canine liquid biopsy is a method of analyzing biomarkers in body fluids (such as blood, urine or saliva) to detect the presence of cancer or monitor the progression of cancer. Unlike traditional tissue biopsies, liquid biopsies are non-invasive, fast and convenient. By obtaining a small blood sample, doctors can analyze free DNA, circulating tumor cells, exosomes, etc. to obtain information about the tumor.

The market for canine cancer screening services is primarily driven by factors such as the aging pet dog population, the rising risk of tumors, increased owner awareness regarding preventive healthcare, and continuous advancements in veterinary diagnostic technologies. As pet dogs are increasingly viewed as family members, owners place greater emphasis on early detection, timely intervention, and improved quality of life; this has shifted the demand for screening from post-symptom diagnostics to routine check-ups for senior dogs, high-risk breeds, and seemingly healthy dogs. Meanwhile, the maturation of technologies—including blood biomarkers, circulating tumor DNA (ctDNA), urine-based molecular testing, genetic sequencing, and AI-driven tumor analysis—has made cancer screening less invasive, more convenient, and applicable to a wider range of clinical scenarios. The expansion of testing networks by veterinary hospitals and reference laboratories, coupled with broader pet insurance coverage and rising veterinary expenditures, has further enhanced service accessibility; however, factors such as test sensitivity, the range of cancer types covered, pricing, result interpretation standards, and the diagnostic confirmation process following a positive result continue to influence the pace of market adoption.

This report presents a comprehensive overview of the global Canine Cancer Screening Services market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Blood-based Screening
• Urine-based Screening
• Others

Segment by Coverage

• Multi-cancer Screening
• Single-cancer Screening
• Others

Segment by Category

• Small Dog
• Medium Sized Dog
• Large Dog

Segment by players, this report covers

• IDEXX Laboratories
• Antech Diagnostics
• VolitionRx
• Fujifilm
• Zoetis Diagnostics
• LABOKLIN
• NationWide Laboratories
• Midwest Vet Labs
• VDI Laboratory
• HT Vet
• Oncotect
• PETcision
• Bioguard Corporation
• CanCan Diagnostics

Segment by Application

• Routine Wellness Screening
• Senior and High-Risk Breed Screening
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Canine Cancer Screening Services market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Routine Wellness Screening, Senior and High-Risk Breed Screening, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact